ADA: Hypo-hyperglycemia minimizer system feasible

June 12, 2012
ADA: hypo-Hyperglycemia minimizer system feasible
The hypoglycemia-hyperglycemia minimizer system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor, and software, is able to predict changes in blood glucose and adjust accordingly, and manipulate insulin delivery compared to corresponding basal rates, according to two studies presented at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.

(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes in blood glucose and adjust accordingly, and manipulate insulin delivery compared to corresponding basal rates, according to two studies presented at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.

Linda Mackowiak, R.N., from Animas Corporation in West Chester, Pa., and colleagues conducted a feasibility trial involving 13 participants at one U.S. site to evaluate the ability of the HHM algorithm to predict a change in above or below set thresholds, and to command the pump to adjust the insulin accordingly. The researchers found that the system was able to predict rises and falls in glucose and adjust accordingly. Advance warnings of significant decreases in CGM glucose were provided by the system. No safety concerns were experienced, including no severe or diabetic ketoacidosis.

Ramakrishna Venugopalan, Ph.D., M.B.A., also from the Animas Corporation, and colleagues assessed the association between CGM trends and the characteristics in a feasibility study. Thirteen participants' basal rate profiles were fine-tuned by the investigator prior to an approximately 20-hour closed-loop control study. The researchers found that, for CGM values below 90 mg/dL, the algorithm dosed participants an average of 85.7 percent less than their corresponding basal rates. The algorithm dosed 42.2 percent more than the corresponding basal rates for CGM readings above 140 mg/dL. No safety concerns were noted, including no diabetic ketoacidosis or severe hypoglycemia.

"The successful completion of this study using the HHM system in a human clinical trial setting is a significant step forward in the development of an advanced first-generation system," an author associated with both studies said in a statement. "It lays the foundation for subsequent clinical trials, bringing us one step closer to making the dream of an artificial pancreas a reality for millions of people living with type 1 diabetes."

The HHM system was developed in a partnership with the Juvenile Diabetes Research Foundation and the insulin-pump maker Animas; several authors disclosed financial ties to Animas.

Explore further: Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

More information: More Information

Related Stories

Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

February 9, 2012
An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia ...

More progress made on artificial pancreas for diabetes patients

June 10, 2012
(HealthDay) -- Progress continues to be made on the development of an artificial pancreas, a device that would ease the burden of living with type 1 diabetes.

Experts find continuous glucose monitoring beneficial in maintaining target blood glucose levels

October 11, 2011
Patients with diabetes face daily challenges in managing their blood glucose levels, and it has been postulated that patients could benefit from a system providing continuous real-time glucose readings. Today, The Endocrine ...

Artificial pancreas may improve overnight control of diabetes in adults

April 15, 2011
Two small randomised trials published in the British Medical Journal today suggest that closed loop insulin delivery (also known as an artificial pancreas) may improve overnight blood glucose control and reduce the risk of ...

Safer and more effective diabetes control with basal insulin analogs

June 24, 2011
Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes. These revolutionary, ...

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.